Mihalis S. Kariolis

Mihalis S. Kariolis

Auto-generated profile, based on publicly available information

Mihalis S. Kariolis

Denali Therapeutics, Inc., South San Francisco, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MKMihalis S. Kariolis
Mihalis S. Kariolis
RWRobert C. Wells
Robert C. Wells
JGJennifer Alice Getz
Jennifer Alice Getz
WKWanda Kwan
Wanda Kwan
CMCathal S. Mahon
Cathal S. Mahon
YZY. Joy Yu Zuchero
Y. Joy Yu Zuchero
Engineering human IgG1 Fc binding to a brain endothelial cell–enriched receptor allows enhanced brain exposure of biotherapeutics in multiple species.

27 May 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JUJulie C. Ullman
Julie C. Ullman
AAAnnie Arguello
Annie Arguello
JGJennifer Alice Getz
Jennifer Alice Getz
Akhil BhallaAkhil Bhalla
Akhil Bhalla
CMCathal S. Mahon
Cathal S. Mahon
AHAnastasia G. Henry
Anastasia G. Henry
An enzyme transport vehicle enables brain delivery of lysosomal enzymes across the blood-brain barrier in mice.
1

19 August 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
KCKylie S. Chew
Kylie S. Chew
RWRobert C. Wells
Robert C. Wells
AMArash Moshkforoush
Arash Moshkforoush
DCDarren Chan
Darren Chan
KLKendra J. Lechtenberg
Kendra J. Lechtenberg
MKMihalis S. Kariolis
Mihalis S. Kariolis
Brain exposure of systemically administered biotherapeutics is highly restricted by the blood-brain barrier (BBB). Here, we report the engineering and characterization of a BBB transport vehicle targeting the CD98 heavy chain (CD98hc or SLC3A2) of heterodimeric amino acid transporters (TVCD98hc). The pharmacokinetic and biodistribution properties of a CD98hc antibody transport vehicle (ATVCD98hc) are assessed in humanized CD98hc knock-in mice and cynomolgus monkeys. Compared to most existing BBB platforms targeting the transferrin receptor, peripherally administered ATVCD98hc demonstrates differentiated brain delivery with markedly slower and more prolonged kinetic properties. Specific biodistribution profiles within the brain parenchyma can be modulated by introducing Fc mutations on ATVCD98hc that impact FcγR engagement, changing the valency of CD98hc binding, and by altering the extent of target engagement with Fabs. Our study establishes TVCD98hc as a modular brain delivery platform with favorable kinetic, biodistribution, and safety properties distinct from previously reported BBB platforms.

26 February 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
AAAnnie Arguello
Annie Arguello
CMCathal S. Mahon
Cathal S. Mahon
MCMeredith E.K. Calvert
Meredith E.K. Calvert
DCDarren Chan
Darren Chan
JDJason C. Dugas
Jason C. Dugas
MKMihalis S. Kariolis
Mihalis S. Kariolis
Delivery of biotherapeutics across the blood–brain barrier (BBB) is a challenge. Many approaches fuse biotherapeutics to platforms that bind the transferrin receptor (TfR), a brain endothelial cell target, to facilitate receptor-mediated transcytosis across the BBB. Here, we characterized the pharmacological behavior of two distinct TfR-targeted platforms fused to iduronate 2-sulfatase (IDS), a lysosomal enzyme deficient in mucopolysaccharidosis type II (MPS II), and compared the relative brain exposures and functional activities of both approaches in mouse models. IDS fused to a moderate-affinity, monovalent TfR-binding enzyme transport vehicle (ETV:IDS) resulted in widespread brain exposure, internalization by parenchymal cells, and significant substrate reduction in the CNS of an MPS II mouse model. In contrast, IDS fused to a standard high-affinity bivalent antibody (IgG:IDS) resulted in lower brain uptake, limited biodistribution beyond brain endothelial cells, and reduced brain substrate reduction. These results highlight important features likely to impact the clinical development of TfR-targeting platforms in MPS II and potentially other CNS diseases.

19 May 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
YMYu Rebecca Miao
Yu Rebecca Miao
KTKaushik N. Thakkar
Kaushik N. Thakkar
JQJin Qian
Jin Qian
MKMihalis S. Kariolis
Mihalis S. Kariolis
WHWei Huang
Wei Huang
AGAmato J. Giaccia
Amato J. Giaccia
Purpose: Ovarian cancer represents a major clinical hurdle for immune checkpoint blockade (ICB), with reported low patient response rates. We found that the immune checkpoint ligand PD-L2 is robustly expressed in patient samples of ovarian cancers and other malignancies exhibiting suboptimal response to ICB but not in cancers that are ICB sensitive. Therefore, we hypothesize that PD-L2 can facilitate immune escape from ICB through incomplete blockade of the PD-1 signaling pathway. Experimental Design: We engineered a soluble form of the PD-1 receptor (sPD-1) capable of binding and neutralizing both PD-L2 and PD-L1 with ×200 and ×10,000 folds improvement in binding affinity over wild-type PD-1 leading to superior inhibition of ligand-mediated PD-1 activities. Results: Both in vitro and in vivo analyses performed in this study demonstrated that the high-affinity sPD-1 molecule is superior at blocking both PD-L1– and PD-L2–mediated immune evasion and reducing tumor growth in immune-competent murine models of ovarian cancer. Conclusions: The data presented in this study provide justification for using a dual targeting, high-affinity sPD-1 receptor as an alternative to PD-1 or PD-L1 therapeutic antibodies for achieving superior therapeutic efficacy in cancers expressing both PD-L2 and PD-L1.

7 August 2025 in Science
Verified
Journal Article
Closed access
MPMichelle E. Pizzo
Michelle E. Pizzo
EPEdward D. Plowey
Edward D. Plowey
NKNathalie Khoury
Nathalie Khoury
WKWanda Kwan
Wanda Kwan
JAJordan Abettan
Jordan Abettan
YZY. Joy Yu Zuchero
Y. Joy Yu Zuchero
Amyloid-related imaging abnormalities (ARIA), side effects of anti-amyloid drugs seen in magnetic resonance imaging of the brain, are a major safety concern in patients with Alzheimer’s disease. We developed an antibody transport vehicle (ATV) targeting transferrin receptor (TfR) for brain delivery of anti-amyloid-β protein (anti-Aβ) using asymmetrical Fc mutations (ATV cisLALA ) that mitigates TfR-related liabilities and retains effector function when bound to Aβ. Administration of ATV cisLALA :Aβ in mice exhibited broad brain distribution and enhanced parenchymal plaque target engagement. This biodistribution reduced ARIA-like lesions and vascular inflammation. Taken together, ATV cisLALA has the potential to improve the next generation of Aβ immunotherapy through enhanced biodistribution mediated by transport across the blood-brain barrier.